Skip to main content
Top
Published in: Drug Safety 2/2008

01-02-2008 | Correspondence

The Author’s Reply

Author: I. Ralph Edwards

Published in: Drug Safety | Issue 2/2008

Login to get access

Excerpt

We were interested to see this letter from Goldstein and colleagues proposing a possible mechanism by which statins may perpetuate neurodegenerative disorder. As they say, however, a proposed mechanism does not resolve the clinical matter. …
Literature
1.
go back to reference Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 2005; 25(1–4): 147–52PubMedCrossRef Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 2005; 25(1–4): 147–52PubMedCrossRef
2.
go back to reference Marcoff L, Thompson PD. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J Am Coll Cardiol 2007; 49(23): 2231–7PubMedCrossRef Marcoff L, Thompson PD. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J Am Coll Cardiol 2007; 49(23): 2231–7PubMedCrossRef
3.
go back to reference Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome: a case report. Eur Neurol 2007; 57(4): 232–5PubMedCrossRef Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome: a case report. Eur Neurol 2007; 57(4): 232–5PubMedCrossRef
Metadata
Title
The Author’s Reply
Author
I. Ralph Edwards
Publication date
01-02-2008
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2008
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200831020-00008

Other articles of this Issue 2/2008

Drug Safety 2/2008 Go to the issue